Seyed Javad M. Moghaddam, MD, ATSF
Department of Pulmonary Medicine, Division of Internal Medicine
About Dr. Seyed Javad M. Moghaddam
Dr. Moghaddam is a tenured research professor in the Department of Pulmonary Medicine with a joint appointment in the Department of Immunology. He was originally trained as an MD but has been functioning as a basic/translational scientist for the past 20+ years. His clinical background, however, has always helped him to have a disease-oriented perspective in his research and enabled him to easily connect basic research to clinical questions and vice versa, which is reflected in disease-oriented translation works published by his group. Dr. Moghaddam is also an active faculty member of UTHealth Houston Graduate School of Biomedical Sciences and served as the director of the Immunology Graduate program for three years in the past. He is an American Thoracic Society Fellow and a three-time recipient of the Lung Cancer Discovery Award from the American Lung Association, as well as a Faculty Excellence Award in Education for mentoring the next generation of biomedical scientists.
Overall, the research in his laboratory focuses on the interplay between inflammation and lung cancer, the second most common type of cancer, and the leading cause of cancer-related mortality worldwide. The most successful, straightforward preventive strategy to reduce the incidence of lung cancer is sustained prevention of tobacco consumption. However, not all individuals respond to behavioral intervention. Furthermore, because of the persistent risk among former smokers, and patients with chronic obstructive pulmonary disease (COPD), as well as increased diagnosis of early-stage lung cancer with the recommended screening method (low-dose CT scan), preventive strategies targeting pathways that stop the progression from premalignant and early-stage lung cancer to advanced stages would be a valuable resource for halting this deadly disease. To this end, his group studies the role of tumor-promoting inflammation, intrinsic (e.g., oncogene-driven) and/or extrinsic (e.g., combustible cigarette smoke, electronic cigarette vapors, or pathogen-induced) in the pathogenesis of lung cancer. His laboratory has developed and interrogated various human-relevant mouse models that closely emulate the molecular pathobiology of human airway inflammation, such as those in COPD and lung adenocarcinoma, and discovered novel targets for preventive and therapeutic purposes. They are currently dissecting the mechanisms of tumor promotion by these inflammatory pathways in a sex- and cell-type specific manner using genetic and pharmacologic (preclinical/translational) approaches in mouse models and clinical samples. His group’s findings and success in preclinically targeting specific inflammatory pathways lay the foundation for the design of personalized and targeted interventions to protract the premalignant lung lesions and their progression in high-risk individual, of whom there are more than 90 million just in the United States.
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Faculty/Mentor, CPRIT Postdoctoral Fellowship in Cancer Prevention Program, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
Faculty/Mentor, First Year Medical Students Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty/Mentor, CPRIT-CURE Training Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty/Mentor, Carl B. and Florence E. King Foundation Summer Program in Biomedical Sciences, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
Faculty, CCSG Lung Cancer Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty/Mentor, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX
Faculty/Mentor, Immunology & Cancer Biology Programs, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX
Faculty/Mentor, Center for Inflammation and Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Tecnologico de Monterrey School of Medicine, Monterrey
Education & Training
Degree-Granting Education
| 1996 | Shahid Beheshti University of Medical Sciences (SBUMS), Tehran, IR, Medicine, MD |
Postgraduate Training
| 2006-2007 | Postdoctoral Research Fellowship, Immunobiology of Lung Cancer, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2006 | Postdoctoral Research Fellowship, Pathobiology of Inflammatory Lung Diseases, Baylor College of Medicine, Houston, Texas |
| 2000-2003 | Postdoctoral Research Fellowship, Inflammatory Bowel Diseases and Colorectal Cancer, Research Center for Gastroenterology and Liver Diseases (RCGLD), SBUMS, Tehran |
| 1994-1996 | Internship, General Internal Medicine, Shahid Beheshti University of Medical Sciences (SBUMS), Tehran |
Licenses & Certifications
| 2025 | GCP for Clinical Trials with Investigational Drugs and Biologics |
| 2023 | EHS- Safety in a Laboratory Environment |
| 2023 | EHS Virus Safety Training |
| 2022 | NIH Eliminating Bias in Peer Review |
| 2022 | NIH Review Integrity |
| 2021 | Research Foundations: Human Subjects Research |
| 2013 | Aseptic Technique for Rodent Survival Surgery |
| 2008 | Introduction to Mice |
| 1996 | Permanent Medical License from Medical Council of Iran |
Experience & Service
Faculty Academic Appointments
Associate Professor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2024
Associate Professor, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Assistant Professor, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Non-Tenure Track Assistant Professor, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2012
Instructor, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2009
Administrative Appointments/Responsibilities
Director, Immunology Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, 2021 - 2024
Intramural Institutional Committee Activities
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Chair, Research Committee, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, IOTOX Retreat Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Academic Policy Advisory Council, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Research Promotion and Harmonization Council, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Research Grand Round Committee, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, The Mid- Career Faculty Academic Leadership Team, The University of Texas MD Anderson Cancer Center, 2020 - Present
Extramural Institutional Committee Activities
Member, Student Success and Well-Being Committee, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, 2024 - Present
Member, Programming Committee, Assembly on Thoracic Oncology (ATO), American Thoracic Society, 2023 - Present
Member, Steering Committee, Gulf Coast Immunology Consortium, 2023 - Present
Editorial Activities
Editor, Cells, 2020 - Present
Associate Editor, Frontiers in Oncology, 2019 - Present
Associate Editor, Frontiers in Immunology, 2019 - Present
Honors & Awards
| 2024 | Faculty Excellence Award in Education, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center |
| 2024 | Faculty Excellence Honoree in Community Outreach, The University of Texas MD Anderson Cancer Center |
| 2023 | Distinguished Faculty Mentor Award Finalist, The University of Texas MD Anderson Cancer Center |
| 2022 | Fellow of American Thoracic Society, American Thoracic Society |
| 2021 | Lung Cancer Discovery Award, American Lung Association |
| 2017 | Early Career Achievement Award in Thoracic Oncology, American Thoracic Society |
| 2017 | Lung Cancer Discovery Award, American Lung Association |
| 2015 | Cyrus Scholar Award in Basic/Translational Research, Cyrus Family Foundation |
| 2011 | Research Scholar Award, American Cancer Society |
| 2009 | Lung Cancer Discovery Award, American Lung Association/LUNGevity Foundation |
| 2008 | Career Development Award, The University of Texas SPORE in Lung Cancer |
| 2007 | Bristol-Meyers Squibb Award in Clinical/Translational Research, The University of Texas MD Anderson Cancer Center |
Professional Memberships
Grant & Contract Support
| Date: | 2024 - 2028 |
| Title: | The Academy at MD Anderson UTHealth Houston Graduate School - Maximizing Opportunities for Training, Development, and Community |
| Funding Source: | NIGMS/NIH |
| Role: | Mentor |
| ID: | 1T32GM152796-01 |
| Date: | 2023 - 2028 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA279452-01A1 |
| Date: | 2023 - 2028 |
| Title: | Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) program |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | 1 R25 CA265800-01A1 |
| Date: | 2022 - 2027 |
| Title: | Retention Fund |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Targeting STAT3 to Prevent Non-Small Cell Lung Cancer (NSCLC) in Patients with Chronic Obstructive Pulmonary Disease (COPD) |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 75N91019D00021 |
| Date: | 2022 - 2027 |
| Title: | Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA272863 |
| Date: | 2022 - 2027 |
| Title: | Spatial and Temporal Tumor-Immune Co-evolution and Interactions That Model Lung Adenocarcinoma Development |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA264583 |
| Date: | 2021 - 2026 |
| Title: | Interplay between host microbiome and immunomodulatory responses in pathogenesis of Kras mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA248731-01A1 |
Selected Publications
Peer-Reviewed Articles
- Korde, A, Ramaswamy, A, Anderson, S, Jin, L, Zhang, JG, Hu, B, Velasco, WV, Diao, L, Wang, J, Pisani, MA, Sauler, M, Boffa, DJ, Puchalski, J, Yan, X, Moghaddam, SM, Takyar, SS. Cigarette smoke induces angiogenic activation in the cancer field through dysregulation of an endothelial microRNA. Communications Biology 8(1), 2025. e-Pub 2025. PMID: 40155749.
- Peng F, Sinjab A, Dai Y, Treekitkarnmongkol W, Yang S, Gomez Bolanos LI, Zhou T, Chen M, Serrano AG, Krishna A, Karimi N, Sharma M, Basi A, Pei G, Liao J, Liu Y, Feng J, Rahal Z, Liu Y, Jiang J, Yu K, Noun T, Liu Y, Khan K, Cho KS, Chen J, Solis LM, Mazzilli S, Dubinett S, Cascone T, Spira AE, Swisher S, Jimbo N, Hayashi T, Kishikawa S, Takamochi K, Itoh T, Yao T, Suzuki K, Kalhor N, Wistuba II, Li M, Moghaddam SJ, Fujimoto J, Burks J, Myers J, Akdemir K, Wang L, Kadara H. Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. Cancer Cell, 2025. e-Pub 2025. PMID: 41202811.
- Deng S, Hussain T, Bartelli TF, Sebastian MM, Zarghooni M, Velasco WV, Somerville B, Phan L, Savage MI, Song Y, Clifford JL, Kadara H, McAllister F, Brown PH, Moghaddam SJ, Aldaz CM. Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer. Mol Cancer Ther, 2025. e-Pub 2025. PMID: 41024580.
- Velasco WV, Grimaldo MT, Karimi N, Clowers MJ, Krishna A, Wu R, Ejaz R, Yuan B, Aguila SD, Bouchelkia I, Barragan JEM, Larsen KE, Rezai Y, Khalaj F, Mitra K, Rodriguez CR, Millares R, de Anda AB, Castro-Pando S, Karandikar UC, Petrosino JF, McAllister F, Kadara H, Ostrin EJ, Fahrmann JF, Hoffman KL, Moghaddam SJ. Comparative effects of combustible cigarette versus electronic cigarette exposures on KRAS mutant lung cancer promotion. Neoplasia 67:101185, 2025. e-Pub 2025. PMID: 40516145.
- Clowers MJ, Rahal Z, Cho SN, Krishna A, Yuan B, Hamana Zorrilla LG, Eckols TK, Kasembeli MM, Liu S, Peng S, Ramos-Castaneda M, Thompson AL, Rodriguez Reyna CI, Larsen KE, Grimaldo MT, Deng S, Karimi N, Chou C, Velasco WV, Zarghooni M, Alekseev S, Solis Soto LM, Ostrin EJ, Kadara H, Ekmekcioglu S, Tweardy DJ, Moghaddam SJ. Selective inhibition of canonical STAT3 signaling suppresses K-ras mutant lung tumorigenesis and reinvigorates anti-tumor immunity. Front Immunol 16:1575181, 2025. e-Pub 2025. PMID: 40356899.
- Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, Chen M, Tarifa Reischle I, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B, Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K, Kadara H. Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment. Cancer Immunol Res 12(12):1736-1752, 2024. e-Pub 2024. PMID: 39269772.
- Castro-Pando S, Howell RM, Li L, Mascaro M, Faraoni EY, Le Roux O, Romanin D, Tahan V, Riquelme E, Zhang Y, Kolls JK, Allison JP, Lozano G, Moghaddam SJ, McAllister F. Pancreatic epithelial IL-17/IL-17RA signaling drives B7-H4 expression to promote tumorigenesis. Cancer Immunol Res 12(9):1170-1183, 2024. e-Pub 2024. PMID: 38842383.
- Velasco WV, Khosravi N, Castro-Pando S, Torres-Garza N, Grimaldo MT, Krishna A, Clowers MJ, Umer M, Tariq Amir S, Del Bosque D, Daliri S, De La Garza MM, Ramos-Castaneda M, Evans SE, Moghaddam SJ. Toll-like receptors 2, 4, and 9 modulate promoting effect of COPD-like airway inflammation on K-ras-driven lung cancer through activation of the MyD88/NF-kB pathway in the airway epithelium. Front Immunol 14(1118721), 2023. e-Pub 2023. PMID: 37283745.
- Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morris R, Liu Y, Tang EL, Viet S, Petersen JL, Lorenzi PL, Tan L, Petrosino J, Hoffman KL, Fujimoto J, Moghaddam SJ, Kadara H. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci 23(18), 2022. e-Pub 2022. PMID: 36142843.
- Yuan B, Clowers MJ, Velasco WV, Peng S, Peng Q, Shi Y, Ramos-Castaneda M, Zarghooni M, Yang S, Babcock RL, Chang SH, Heymach JV, Zhang J, Ostrin EJ, Watowich SS, Kadara H, Moghaddam SJ. Targeting IL-1β as an immune preventive and therapeutic modality for K-ras mutant lung cancer. JCI Insight 1(11):e157788, 2022. e-Pub 2022. PMID: 35471938.
- Deng S, Ramos-Castaneda M, Velasco WV, Clowers MJ, Gutierrez BA, Noble O, Dong Y, Zarghooni M, Alvarado L, Caetano MS, Yang S, Ostrin EJ, Behrens C, Wistuba II, Stabile LP, Kadara H, Watowich SS, Moghaddam SJ. Interplay between Estrogen and Stat3/NF-κB Driven Immunomodulation in Lung Cancer. Carcinogenesis 41(11):1529-1542, 2020. e-Pub 2020. PMID: 32603404.
- Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun 9(1):4589, 2018. e-Pub 2018. PMID: 30389925.
- De la Garza MM, Cumpian AM, Daliri S, Castro-Pando S, Umer M, Gong L, Khosravi N, Caetano MS, Ramos-Castañeda M, Flores AG, Beltran EC, Tran HT, Tuvim MJ, Ostrin EJ, Dickey BF, Evans CM, Moghaddam SJ. COPD-Type lung inflammation promotes K-ras mutant lung cancer through epithelial HIF-1α mediated tumor angiogenesis and proliferation. Oncotarget 9(68):32972-32983, 2018. e-Pub 2018. PMID: 30250643.
- Bauer AK, Umer M, Richardson VL, Cumpian AM, Harder AQ, Khosravi N, Azzegagh Z, Hara NM, Ehre C, Mohebnasab M, Caetano MS, Merrick DT, van Bokhoven A, Wistuba II, Kadara H, Dickey BF, Velmurugan K, Mann PR, Lu X, Barón AE, Evans CM, Moghaddam SJ. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight 3(15), 2018. e-Pub 2018. PMID: 30089720.
- Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, Daliri S, Hernandez BJ, Gutierrez BA, Evans SE, Hanash S, Alekseev AM, Yang Y, Chang SH, Nurieva R, Kadara H, Chen J, Ostrin EJ, Moghaddam SJ. IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties. Cancer Immunol Res 6(7):788-797, 2018. e-Pub 2018. PMID: 29764837.
- Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, Behrens C, Wistuba II, Sternberg C, Kadara H, Ferreira CG, Watowich SS, Moghaddam SJ. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. Cancer Res 76(11):3189-99, 2016. e-Pub 2016. PMID: 27197187.
- Gong L, da Silva Caetano M, Cumpian AM, Daliri S, Garza Flores A, Chang SH, Ochoa CE, Evans CM, Yu Z, Moghaddam SJ. Tumor Necrosis Factor Links Chronic Obstructive Pulmonary Disease and K-ras Mutant Lung Cancer Through Induction of an Immunosuppressive Pro-tumor Microenvironment. Oncoimmunology 5(10):e1229724, 2016. e-Pub 2016. PMID: 27853654.
- Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C. T Helper 17 Cells Play a Critical Pathogenic Role in Lung Cancer. Proc Natl Acad Sci U S A 111(15):5664-9, 2014. e-Pub 2014. PMID: 24706787.
- Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, Mirabolfathinejad SG, Dickey BF, Zhou Q, Moghaddam SJ. Promoting Effect of Neutrophils on Lung Tumorigenesis Is Mediated by CXCR2 and Neutrophil Elastase. Mol Cancer 12(1):154, 2013. e-Pub 2013. PMID: 24321240.
- Barta P, Van Pelt C, Men T, Dickey BF, Lotan R, Moghaddam SJ. Enhancement of Lung Tumorigenesis in a Gprc5a Knockout Mouse by Chronic Extrinsic Airway Inflammation. Mol Cancer 11(1):4, 2012. e-Pub 2012. PMID: 22239913.
- Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, Dickey BF, Moghaddam SJ. Interleukin 6 But Not T helper 2 Cytokines Promotes Lung Carcinogenesis. Cancer Prev Res (Phila) 4(1):51-64, 2011. e-Pub 2011. PMID: 21098042.
- Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar-Aouchiche Z, Garza NT, Vo TT, Newman RA, Aggarwal BB, Evans CM, Tuvim MJ, Lotan R, Dickey BF. Curcumin Inhibits COPD-Like Airway Inflammation and Lung Cancer Progression in Mice. Carcinogenesis. Carcinogenesis 30(11):1949-56, 2009. e-Pub 2009. PMID: 19793800.
- Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ. Promotion of Lung Carcinogenesis by COPD-Like Airway Inflammation in a K ras Induced Mouse Model. Am J Respir Cell Mol Biol 40(4):443-53 (Cover Art), 2009. e-Pub 2009. PMID: 18927348.
- Moghaddam SJ, Clement CG, De la Garza MM, Zou X, Travis EL, Young HW, Evans CM, Tuvim MJ, Dickey BF. Haemophilus influenzae Lysate Induces Aspects of the Chronic Obstructive Pulmonary Disease Phenotype. Am J Respir Cell Mol Biol 38(6):629-38 (Cover), 2008. e-Pub 2008. PMID: 18096867.
Invited Articles
- Rahal, Z, El Darzi, R, Moghaddam, SM, Cascone, T, Kadara, HN. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nature Reviews Clinical Oncology 22(7):463-482, 2025. e-Pub 2025. PMID: 40379986.
- Moghaddam SJ, Savai R, Salehi-Rad R, Sengupta S, Kammer MN, Massion P, Beane JE, Ostrin EJ, Priolo C, Tennis MA, Stabile LP, Bauer AK, Sears CR, Szabo E, Rivera MP, Powell CA, Kadara H, Jenkins BJ, Dubinett SM, Houghton AM, Kim CF, Keith RL. Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 210(5):548-571, 2024. e-Pub 2024. PMID: 39115548.
- Karimi N, Moghaddam SJ. KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions. Cells 12(5), 2023. e-Pub 2023. PMID: 36899885.
- Clowers MJ, Moghaddam SJ. Cell Type-Specific Roles of STAT3 Signaling in the Pathogenesis and Progression of K-ras Mutant Lung Adenocarcinoma. Cancers (Basel) 14(7), 2022. e-Pub 2022. PMID: 35406557.
- Deng S, Clowers MJ, Velasco WV, Ramos-Castaneda M, Moghaddam SJ. Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment. Front Oncol 9(1556), 2020. e-Pub 2020. PMID: 32039025.
- Moghaddam SJ, Ochoa CE, Sethi S, Dickey BF. Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Lung Cancer. Int J Chron Obstruct Pulmon Dis 6:113-23, 2011. e-Pub 2011. PMID: 21407824.
Book Chapters
- Karimi N, De Anda AB, Yang R, Aksan E, Grimaldo MT, Moghaddam SJ. The Multipotential Effect of Microbiome in Lung Cancer Development and Progression. In: Int Rev Cell Mol Biol, 171-196, 2025.
- Ramos-Castaneda M, Moghaddam SJ. Lung Cancer Murine Models and Methodology for Immunopreventive Study. In: Methods Mol Biol. Springer Science, 203-214, 2022.
- Velasco WV, Ramos-Castaneda M, Clowers MJ, Deng S, Moghaddam SJ. KRAS: The Art of Understanding a Complex Gene. Reference Module in Biomedical Sciences. In: Encyclopedia of Respiratory Medicine. 2. Elsevier, 876–888, 2020.
- Sharafkhaneh A, Velamuri S, Moghaddam SJ, Badmaev V, Dickey B, Kurie J. Natural Agents for Chemoprevention of Lung Cancer. In: Lung Cancer. Blackwell, 2008.
Patient Reviews
CV information above last modified July 22, 2026